Mumbai, June 19, 2009: Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted an approval for its Abbreviated New Drug Application (ANDA) for generic Accupril®, quinapril hydrochloride tablets.
These quinapril hydrochloride tablets, therapeutically equivalent to Accupril® tablets from Pfizer, are available in four strengths viz. 5 mg, 10 mg, 20 mg and 40 mg and have annual sales of approximately USD 45 million in the US.
Quinapril is an antihypertensive.
Accupril® is a registered trademark of Pfizer.
The stock closed the day at Rs.1313.55, down by Rs.3.10 or 0.24%. The stock hit an intraday high of Rs.1347.90 and low of Rs.1290.
The total traded quantity was 19683 compared to 2 week average of 23460.
|
